Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares U.S. Healthcare ETF (NY:IYH)

71.05 -0.52 (-0.72%)
Delayed Quote Updated: 11:18 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about iShares U.S. Healthcare ETF

< Previous 1 2 3 4 Next >
News headline image
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗
IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income. 
Via The Motley Fool
Topics ETFs
News headline image
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? ↗
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets. 
Via The Motley Fool
Topics ETFs
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗
Via Stocktwits
FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report ↗
Via Stocktwits
News headline image
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits ↗
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors. 
Via The Motley Fool
Topics ETFs
News headline image
IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors. 
Via The Motley Fool
Topics ETFs
News headline image
Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗
FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield? ↗
State Street's fund charges just 0.08% annually versus 0.38% for iShares, but the broader portfolio offers 100 holdings versus 60. 
Via The Motley Fool
Topics ETFs
News headline image
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK ↗
The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors... 
Via The Motley Fool
Topics ETFs
News headline image
Health Care ETFs: XLV Delivers Low Fees and Solid Returns ↗
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026? ↗
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did IXHL Stock Tank Over 32% Today? ↗
The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 
Via Stocktwits
News headline image
Why Did GERN Stock Tumble 10% Pre-Market Today? ↗
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗
The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp. 
Via Stocktwits
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
Via Stocktwits
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry ↗
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead. 
Via Stocktwits
Topics Intellectual Property
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
Why Did IMUX Stock Surge 33% Pre-Market Today? ↗
Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs. 
Via Stocktwits
News headline image
Why Did Healthcare Triangle Stock Plummet 20% Today? ↗
The technology firm announced that it will implement a 1-for-60 reverse stock split of its common shares effective at 12:01 a.m. Eastern Time on February 10. 
Via Stocktwits
News headline image
Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone. 
Via Stocktwits
News headline image
Monster Beverage, UnitedHealth, Thermo Fisher Scientific And More: CNBC's 'Final Trades' ↗
Today's "Final Trades" segment focused on UnitedHealth, Thermo Fisher Scientific, iShares U.S. Healthcare ETF and Monster Beverage. 
Via Benzinga
Topics ETFs
News headline image
Why Is Co-Diagnostics Stock Sinking Tuesday? ↗
Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint venture, causing concerns about dilution. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.